MedTrace Logo

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

NCT00005072 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-07-29

No results posted yet for this study

Summary

RATIONALE: Inserting the gene for interleukin-2 into a person's prostate cancer cells may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of Leuvectin in treating patients who have locally recurrent prostate cancer after receiving treatment with radiation therapy.

Conditions

Interventions

BIOLOGICAL

Leuvectin

1000 ug of Leuvectin injected intratumorally

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vical

    lead INDUSTRY

Principal Investigators

  • Arie Belldegrun, MD, FACS · Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2003-04-30
Completion
2003-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005072 on ClinicalTrials.gov